Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination.
Annika M JödickeIvanka CurkovicUrs ZellwegerIvan T TomkaThomas NeuerGerd A Kullak-UblickMalgorzata RoosMarco EgbringPublished in: The Annals of pharmacotherapy (2018)
The relative frequencies of X- and D-pDDIs were 0.4% and 6.65%, respectively. In the cohort study, significant associations between exposure to tizanidine and ciprofloxacin and outpatient physician visits were identified for 14 and 30 days (odds ratio [OR] = 1.61 [95% CI = 1.17-2.24], P = 0.004, and OR = 1.59 [95% CI = 1.1-2.34], P = 0.016). A trend for increased risk of hospitalization was found for all evaluated time periods (OR = 1.68 [95% CI = 0.84-3.17], OR = 1.52 [95% CI = 0.63-3.33], and OR = 2.19 [95% CI = 0.88-5.02]). Conclusion and Relevance: The interaction between tizanidine and ciprofloxacin is not only relevant for individual patients, but also at the population level. Further investigation of the impact of other clinically relevant DDIs is necessary to improve patient safety and reduce avoidable health care utilization.
Keyphrases
- patient safety
- pseudomonas aeruginosa
- healthcare
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- emergency department
- quality improvement
- primary care
- health insurance
- electronic health record
- big data
- patient reported outcomes
- machine learning
- artificial intelligence
- data analysis
- health information